

Sethera Therapeutics Appoints Jeffery W. Kelly and Alexander M. Klibanov to Scientific Advisory Board

SALT LAKE CITY, UT, UNITED STATES, September 25, 2025 /EINPresswire.com/ -- [Sethera Therapeutics](#), a biotechnology company advancing next-generation polymacrocyclic peptide therapeutics, today announced the appointment of two globally recognized scientists, Jeffery W. Kelly, PhD (Scripps Research), and Alexander M. Klibanov, PhD (MIT), to its Scientific Advisory Board (SAB). They join existing SAB member Dr. Robert Langer (MIT) in guiding Sethera's scientific strategy.

Jeffery W. Kelly, PhD, the Lita Annenberg Hazen Professor of Chemistry at Scripps Research, is a pioneer in the field of protein folding and proteostasis. He is best known for elucidating the molecular basis of transthyretin (TTR) amyloidosis and leading the discovery of tafamidis (Vyndaqel)—the first disease-modifying TTR stabilizer, now marketed by Pfizer. Dr. Kelly's work has earned him prestigious accolades, including the 2022 Breakthrough Prize in Life Sciences and the 2023 Wolf Prize in Chemistry. At Sethera, he will advise on the translation of conformationally constrained macrocyclic peptide designs into clinically meaningful therapeutics targeting complex disease mechanisms.

Alexander M. Klibanov, PhD, the Novartis Professor of Chemistry (Emeritus) at MIT, is internationally recognized for groundbreaking work in enzyme catalysis, protein formulation, and the development of antimicrobial materials. A member of both the U.S. National Academy of Sciences and the National Academy of Engineering, Dr. Klibanov has made seminal contributions to the stabilization and delivery of protein-based therapeutics. His deep expertise will support Sethera's advancement of enzymatically engineered peptide candidates toward clinical development.

"Sethera's platform sits at the nexus of structure and function," said Karsten Eastman, PhD, Co-founder and CEO of Sethera Therapeutics. "Dr. Kelly's leadership in proteostasis and chemical biology, combined with Dr. Klibanov's innovations in enzymatic engineering and formulation, directly align with our mission to transform polymacrocyclic peptide architectures into first-in-class therapeutics for historically intractable targets."

About Sethera Therapeutics

Sethera Therapeutics is a biotechnology company pioneering enzymatic macrocyclization to create polymacrocyclic peptides—multi-macrocyclic, stapled scaffolds that bridge the gap

between small molecules and biologics. Sether's platform combines ultra-large-scale discovery with orthogonal validation to unlock "undruggable" targets across oncology, metabolic disease, infectious disease, and beyond.

Learn more at www.setheratx.com

Karsten Eastman

Sether Therapeutics, Inc.

+1 801-850-4367

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/852480040>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.